TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33273674

Group type: EXPERIMENTAL
Intervention: 100% soybean plant
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intermediate addition of sugarcane
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sugarcane levels (25-50%)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: C50 soybean genotype
Number of subjects: 4
Study: 34995296

Group type: EXPERIMENTAL
Intervention: Maternal feeding styles and practices at child age 5 months
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Maternal feeding styles and practices at child age 12 months
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Maternal feeding styles and practices at child age 24 months
Number of subjects: 474
Study: 32284265

Group type: EXPERIMENTAL
Intervention: Asthma prevalence in 2002, 2006, and 2016
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current wheeze prevalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise-induced wheeze prevalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Night dry cough prevalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asthma likelihood by year
Number of subjects: 0
Study: 33724542

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) 50 mg/week
Number of subjects: 16071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16071
Study: 32128995

Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (CRD) for 8 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (CRD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fat-restricted diet (FRD)
Number of subjects: 32
Study: 36203183

Group type: EXPERIMENTAL
Intervention: Virtual Simulation (VS)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual Supervised Work (SW)
Number of subjects: 95
Study: 33662902

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (LPV) with tidal volume 6 ml/kg PBW + PEEP 7 cmH2O
Number of subjects: 258

Group type: COMPARATOR
Intervention: Nonprotective ventilation (control group) with tidal volume 9 ml/kg PBW without PEEP
Number of subjects: 258
Study: 32055940

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (IH)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Continuous hypoxia (CH)
Number of subjects: 15
Study: 36322001

Group type: EXPERIMENTAL
Intervention: Increased physical activity program (n=40)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (n=39)
Number of subjects: 79
Study: 33559435

Group type: EXPERIMENTAL
Intervention: Tiaoshen acupuncture method combined with electroacupuncture (EA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Electroacupuncture (EA) alone
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (Tiaoshen and EA)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Tiaoshen group
Number of subjects: 76
Study: 33223365

Group type: EXPERIMENTAL
Intervention: Dual-plane polyglactin mesh supported IBR (n=91)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Subpectoral IBR (n=117)
Number of subjects: 190
Study: 34326500

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 327
Study: 33988519

Group type: EXPERIMENTAL
Intervention: Txt2Prevent (SMS text messaging intervention)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study: 34310276

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Pain (CBT‐P)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 32
Study: 34706856

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 70

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 70
Study: 36343068

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMFT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (conventional physical therapy treatment)
Number of subjects: 56
Study: 35510814

Group type: EXPERIMENTAL
Intervention: Transition workshop (ModuS‐T)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (regular medical care)
Number of subjects: 56
Study: 33328333

Group type: EXPERIMENTAL
Intervention: IL-2/UFKA-20 complexes
Number of subjects: 0
Study: 36301013

Group type: EXPERIMENTAL
Intervention: Video intervention (VD)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Oral counselling (OR)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Oral counselling with App (OR + App)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Video with App (VD + App)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Oral counselling without App (OR without App)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Video without App (VD without App)
Number of subjects: 291
Study: 33938493

Group type: EXPERIMENTAL
Intervention: HAI FUDR + SYS FOLFIRI + Pmab
Number of subjects: 75

Group type: COMPARATOR
Intervention: HAI FUDR + SYS FOLFIRI
Number of subjects: 75
Study: 35930415

Group type: EXPERIMENTAL
Intervention: Tailored parenting plans generated by a computerized algorithm based on participants' responses to the Sickle Cell Reproductive Health Knowledge Parenting Intent Questionnaire.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-based genetic inheritance education (as a context for the intervention).
Number of subjects: 0
Study: 32748630

Group type: EXPERIMENTAL
Intervention: TMS (10 Hz, 700 pulses for four weeks)
Number of subjects: 60
Study: 36410806

Group type: EXPERIMENTAL
Intervention: Stepwise individually titrated increase of dialysate magnesium concentration from 0.50 to 0.75 to 1.00 mmol/L during 8 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard dialysate magnesium concentration of 0.50 mmol/L
Number of subjects: 53
Study: 32084330

Group type: EXPERIMENTAL
Intervention: DNA methylation at 18 CpGs
Number of subjects: 400102

Group type: EXPERIMENTAL
Intervention: DNA methylation at three specific CpGs (cg21201401, cg19758448, cg12616487)
Number of subjects: 400102

Group type: COMPARATOR
Intervention: DNA methylation mediation
Number of subjects: 400102

Group type: EXPERIMENTAL
Intervention: Shared causal variants analysis using 'moloc' framework
Number of subjects: 400102
Study: 36178575

Group type: EXPERIMENTAL
Intervention: ≥ 10 lymph node dissections (LNDs)
Number of subjects: 26517

Group type: COMPARATOR
Intervention: ≤ 9 lymph node dissections (LNDs)
Number of subjects: 26517
Study: 34319514

Group type: EXPERIMENTAL
Intervention: Hydrogen gas inhalation (6.5 vol% in 2 L/min of mixed air) for 16 weeks, twice a day for 1 hour
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo air inhalation for 16 weeks, twice a day for 1 hour
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrogen gas inhalation
Number of subjects: 20
Study: 33032806

Group type: EXPERIMENTAL
Intervention: Inhalational anesthesia
Number of subjects: 105

Group type: COMPARATOR
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 105
Study: 35279301

Group type: EXPERIMENTAL
Intervention: Locally developed dental implants (test group)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Imported dental implants (control group)
Number of subjects: 136
Study: 33200812

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of 10 mg rosuvastatin and ezetimibe administered in the morning for 6 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of 10 mg rosuvastatin and ezetimibe administered in the evening for 6 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Morning administration of the drug
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Evening administration of the drug
Number of subjects: 83

Group type: COMPARATOR
Intervention: Morning vs Evening drug administration
Number of subjects: 83
Study: 36109314

Group type: EXPERIMENTAL
Intervention: Grooved ureteral stent
Number of subjects: 42

Group type: COMPARATOR
Intervention: Smooth-walled ureteral stent
Number of subjects: 42
Study: 33229339

Group type: EXPERIMENTAL
Intervention: Supplemental calcium (1,200 mg/day) and/or vitamin D3 (1,000 IU/day)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 175
Study: 36104929

Group type: EXPERIMENTAL
Intervention: DT catheter (50 W, 9 s)
Number of subjects: 113

Group type: COMPARATOR
Intervention: AI-guided ablation (AI anterior 550; AI posterior 400)
Number of subjects: 113
Study: 34199006

Group type: EXPERIMENTAL
Intervention: Dairy-based product (DP) containing protein, galacto-oligosaccharides, vitamins, and minerals, consumed 1 hour before bedtime for three weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dairy-based product (DP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (skimmed milk)
Number of subjects: 70
Study: 34619378

Group type: EXPERIMENTAL
Intervention: Desflurane with remifentanil (Group D: n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol with remifentanil (Group P: n=25)
Number of subjects: 50
Study: 33675289

Group type: EXPERIMENTAL
Intervention: Gamified educational webinar
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-gamified educational webinar
Number of subjects: 52
Study: 32736622

Group type: EXPERIMENTAL
Intervention: Antenatal care (ANC)
Number of subjects: 3758

Group type: EXPERIMENTAL
Intervention: Delivery care
Number of subjects: 3758

Group type: EXPERIMENTAL
Intervention: Postnatal care (PNC)
Number of subjects: 3758

Group type: EXPERIMENTAL
Intervention: Maternity waiting homes (MWH)
Number of subjects: 3758
Study: 34519446

Group type: EXPERIMENTAL
Intervention: NIC intervention Fall prevention
Number of subjects: 118
Study: 33328161

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35101110

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy, off-label subretinal TPA up to 25 μg in 0.25 ml, intravitreal 20% sulfahexafluoride gas, and intravitreal aflibercept.
Number of subjects: 210

Group type: COMPARATOR
Intervention: Intravitreal aflibercept monotherapy.
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both groups received intravitreal aflibercept 2 mg administered monthly for 3 doses, then 2-monthly to month 12.
Number of subjects: 210
Study: 33738656

Group type: EXPERIMENTAL
Intervention: Two courses of DCF (70 mg/m2 intravenous docetaxel and 70 mg/m2 intravenous cisplatin on day 1, and a continuous 700 mg/m2 fluorouracil infusion for 5 days) every 3 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Three courses of DCF (70 mg/m2 intravenous docetaxel and 70 mg/m2 intravenous cisplatin on day 1, and a continuous 700 mg/m2 fluorouracil infusion for 5 days) every 3 weeks
Number of subjects: 180
Study: 32230729

Group type: EXPERIMENTAL
Intervention: High-γ-PGA natto meal (WR + high-γ-PGA natto)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-γ-PGA natto meal (WR + low-γ-PGA natto)
Number of subjects: 0

Group type: COMPARATOR
Intervention: White rice (WR)
Number of subjects: 0
Study: 35014069

Group type: EXPERIMENTAL
Intervention: ALKS 7119 (≥50 mg)
Number of subjects: 100
Study: 32472307

Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 32723670

Group type: EXPERIMENTAL
Intervention: SPN-812 100 mg/day
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: SPN-812 200 mg/day
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study: 34653384

Group type: EXPERIMENTAL
Intervention: Poloxamer 407-based 0.75% ropivacaine hydrogel (22.5 mg)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Continuous thoracic paravertebral block using On‐Q (0.2% ropivacaine, 4 mg/h for 48 hours)
Number of subjects: 89
Study: 33661917

Group type: EXPERIMENTAL
Intervention: Serum tricosanoyl sphingomyelin (d18:1/23:0) levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sixteen metabolites including cotinine, N‐delta‐acetylornithine, and sphingomyelin (d17:1/24:1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sphingolipid markers
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Genetic variants in sphingolipid pathway genes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epigenomic analyses
Number of subjects: 50
Study: 33549435

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: High Carbohydrate (HC) diet
Number of subjects: 24
Study: 35277540

Group type: EXPERIMENTAL
Intervention: bococizumab
Number of subjects: 8844
Study: 34608329

Group type: EXPERIMENTAL
Intervention: Islatravir 54 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Islatravir 62 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 32847980

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTC count pre-cycle 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTC count post-treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Declination in CTCs
Number of subjects: 0
Study: 35363262

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (FFX)
Number of subjects: 0
Study: 32056982

Group type: EXPERIMENTAL
Intervention: 200-m sprint
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 500-m sprint
Number of subjects: 13
Study: 35142582

Group type: EXPERIMENTAL
Intervention: Daratumumab-based triplet therapies (VGPR or better)
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Daratumumab-based triplet therapies (MRD negativity)
Number of subjects: 883
Study: 32365314

Group type: EXPERIMENTAL
Intervention: Nighttime orthosis on the second or third finger of the dominant hand
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 52
Study: 33216196

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 10 mg/kg/day, orally
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vitamin E 10 U/kg/day, orally
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 33444565

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 IU monthly)
Number of subjects: 21315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21315
Study: 32476800

Group type: EXPERIMENTAL
Intervention: HR‐T2WI
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: DCE‐T1
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: ADC
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Multi‐modal radiomics model
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Clinical radiomics nomogram
Number of subjects: 118
Study: 33548908

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg once daily for 12 weeks
Number of subjects: 300
Study: 32438012

Group type: EXPERIMENTAL
Intervention: Purdue Pegboard Test (PPT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Handgrip force task
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: fMRI activity in sensorimotor areas
Number of subjects: 27
Study: 35981821

Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy (SAPT) for 11 months (or 5 months in patients on oral anticoagulation)
Number of subjects: 4579

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) for ≥2 months followed by SAPT
Number of subjects: 4579

Group type: COMPARATOR
Intervention: Single antiplatelet therapy (SAPT)
Number of subjects: 4579
Study: 33411910

Group type: EXPERIMENTAL
Intervention: 12 g/day of fructooligosaccharide (FOS) for 3 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for 3 months
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Prebiotic group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FOS
Number of subjects: 46
Study: 32199491

Group type: EXPERIMENTAL
Intervention: ChAd3‐EBO‐Z
Number of subjects: 3013

Group type: COMPARATOR
Intervention: Placebo/ChAd3‐EBO‐Z
Number of subjects: 3013
Study: 35360270

Group type: EXPERIMENTAL
Intervention: Continuous nursing (intervention group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine nursing (control group)
Number of subjects: 82
Study: 32929612

Group type: EXPERIMENTAL
Intervention: ASP8232
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34022365

Group type: EXPERIMENTAL
Intervention: Tenotomy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Tenodesis
Number of subjects: 114
Study: 32207575

Group type: EXPERIMENTAL
Intervention: 25 mg/ml tranexamic acid (TXA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 202
Study: 36352399

Group type: EXPERIMENTAL
Intervention: Temperature-controlled Laminar Airflow (TLA)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 34836014

Group type: EXPERIMENTAL
Intervention: ASI + I (Inositol‐enhanced bonded arginine silicate) 1600 mg
Number of subjects: 26
Study: 37661604

Group type: EXPERIMENTAL
Intervention: Cryomodulation treatment (10-min controlled cooling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryomodulation treatment
Number of subjects: 0
Study: 34241762

Group type: EXPERIMENTAL
Intervention: Low genistein doses (10 µg/g body weight)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: High genistein doses (100 µg/g body weight)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 17-estradiol (E2) (10 µg/g body weight)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (vehicle only)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Blank (no injection)
Number of subjects: 300
Study: 34962574

Group type: EXPERIMENTAL
Intervention: Dopamine agonist
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: MAO-B inhibitor
Number of subjects: 500

Group type: COMPARATOR
Intervention: COMT inhibitor
Number of subjects: 500

Group type: COMPARATOR
Intervention: Dopamine agonist vs MAO-B inhibitors
Number of subjects: 500

Group type: COMPARATOR
Intervention: Dopamine agonist and MAO-B inhibitors
Number of subjects: 500
Study: 33514292

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 1144
Study: 33085647

Group type: EXPERIMENTAL
Intervention: Cerebellar intermittent theta burst stimulation (iTBS), 10-day treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 32615020

Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 97
Study: 32421267

Group type: EXPERIMENTAL
Intervention: Quality of emergency patients' information in the hospital information system
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Accuracy
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Completeness
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Timeliness
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Definition
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Accessibility
Number of subjects: 385
Study: 35272843

Group type: EXPERIMENTAL
Intervention: Exa Cerapol polishing kit
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Shofu polishing kit
Number of subjects: 96
Study: 34274609

Group type: EXPERIMENTAL
Intervention: Neural network architecture for estimating left ventricle volume
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Neural network segmentation of left ventricle
Number of subjects: 397
Study: 34033624

Group type: EXPERIMENTAL
Intervention: COOL (2°C water perfusing a top for 2 min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: CON (no cooling)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: COOL
Number of subjects: 7

Group type: COMPARATOR
Intervention: COOL and CON
Number of subjects: 7
Study: 35597600

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 0
Study: 32330929

Group type: EXPERIMENTAL
Intervention: Protein profiles at birth
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Protein profiles at 1 week postnatally
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Protein profiles up to term-equivalent age
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clusters of proteins identified
Number of subjects: 14
Study: 32266595

Group type: EXPERIMENTAL
Intervention: Predictive nomogram and web-based survival rate calculator for cancer-specific survival.
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Independent risk factors identified: age, race, T stage, N stage, M stage, surgery, radiotherapy, chemotherapy, marital status.
Number of subjects: 2007
Study: 33858488

Group type: EXPERIMENTAL
Intervention: Short protocol (20 ECT sessions over 6 months)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Long protocol (40 ECT sessions over 12 months)
Number of subjects: 64
Study: 33151126

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) levels in PD patients
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D levels
Number of subjects: 500
Study: 32486874

Group type: EXPERIMENTAL
Intervention: Opioids plus gabapentinoids
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Opioids
Number of subjects: 1059
Study: 33307555

Group type: EXPERIMENTAL
Intervention: HIITSM (10 HIIT sessions over 13 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: HIITTRAD (4 HIIT sessions over 13 days)
Number of subjects: 19
Study: 33148502

Group type: EXPERIMENTAL
Intervention: RSA-biofeedback with treatment as usual (BFB + TAU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study: 34850173

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 4619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4619

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4619
Study: 34836235

Group type: EXPERIMENTAL
Intervention: 200 mg of PXN
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study: 32576447

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 15) - LCI-triggered bronchoalveolar lavage (BAL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (n = 14) - Standard care without LCI-triggered BAL
Number of subjects: 29
Study: 34784246

Group type: COMPARATOR
Intervention: Lumbar spine treatment only (LBO group)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Lumbar spine and hip treatments (LBH group)
Number of subjects: 76